Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.

Abstract excerpt

PURPOSE: The treatment landscape for chronic myeloid leukemia (CML) has been revolutionized by the introduction of imatinib, a tyrosine kinase inhibitor, which has transformed the disease from a fatal condition into a manageable chronic illness for a substantial number of patients. Despite this, some individuals do not respond adequately to the treatment, and others may experience disease progression even with...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• ATP Binding Cassette Transporter, Subfamily G, Member 2
• Cytochrome P-450 CYP2C8
• Egypt
• Imatinib Mesylate